- Home
- CNTA vs SUPN Comparison
CNTA vs SUPN Comparison
Compare CNTA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | SUPN |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.6B |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CNTA | SUPN |
|---|---|---|
| Price | $24.81 | $49.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $37.70 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.2M | 634.2K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,000,000.00 | ★ $681,539,000.00 |
| Revenue This Year | N/A | $8.32 |
| Revenue Next Year | N/A | $23.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 118.88 | 4.54 |
| 52 Week Low | $9.60 | $29.16 |
| 52 Week High | $30.58 | $57.65 |
Technical Indicators
Market Signals| Indicator | CNTA | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 56.15 |
| Support Level | $24.17 | $51.01 |
| Resistance Level | $26.01 | $52.30 |
| Average True Range (ATR) | 1.17 | 1.40 |
| MACD | -0.31 | 0.35 |
| Stochastic Oscillator | 11.28 | 64.48 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.